Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

BACKGROUND: Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socializ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Frenck, Robert W., Klein, Nicola P., Kitchin, Nicholas, Gurtman, Alejandra, Absalon, Judith, Lockhart, Stephen, Perez, John L., Walter, Emmanuel B., Senders, Shelly, Bailey, Ruth, Swanson, Kena A., Ma, Hua, Xu, Xia, Koury, Kenneth, Kalina, Warren V., Cooper, David, Jennings, Timothy, Brandon, Donald M., Thomas, Stephen J., Türeci, Özlem, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Jansen, Kathrin U., Gruber, William C.
Format: Artigo
Idioma:Inglês
Publicat: Massachusetts Medical Society 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8174030/
https://ncbi.nlm.nih.gov/pubmed/34043894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107456
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars